Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT06773663

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 1/2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06773663
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06773663. Allocation not applicable; no masking; primary purpose diagnostic. Start 2023-12-30 (actual); primary completion 2026-05-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism
Condition
Primary Aldosteronism
Condition
Primary Aldosteronism Due to Aldosterone Producing Adenoma
Intervention (Combination product)
Al18F-NOTA-Pentixafor PET/CT
Lead sponsor
Peking Union Medical College Hospital (class: other)

Record details

Record id
cardio:ct-nct06773663
Content hash
56a60ae3eee5b553e60dcd6827684b04b9eee5c2976abc26f3598352740a65ae